The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017:
30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017:
Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma
Campral ... Read More
13
Apr2017
28
Mar2017
The updated guidelines recognize the substantial advances that have been made in the methods of economic evaluation and they offer up-to-date guidance on the best practices for determining the economic value of health technologies.
Available for download at the following link.
17
Mar2017
New CADTH Processes
Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals
In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ... Read More
16
Mar2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017:
33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017:
Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More
15
Mar2017
CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada.
The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ... Read More
15
Mar2017
INESSS Upcoming Meetings with Manufacturers – October 2017 “Liste des médicaments”
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the March 24, 2017 deadline for drugs to be listed on the October 2017 “Liste des médicaments". These meetings will be held between April ... Read More
17
Feb2017
This is a reminder to all patentees of their filing requirements to the PMPRB respecting revenues and research and development expenditures. All patentees must submit their Form 3 information for 2016 by March 1, 2017.
These filing requirements are contained in section 5 of the Patented Medicines Regulations.
As part of their ... Read More
06
Feb2017
Kaitlyn Proulx appointed Managing Director / Directrice Générale
Neil Palmer, Founder and Principal Consultant of PDCI Market Access Inc is pleased to announce the appointment of Kaitlyn Proulx as Managing Director. As Managing Director, Kaitlyn manages PDCI’s operations and leads the firm’s pricing and market access consulting teams from PDCI’s headquarters ... Read More
06
Dec2016
On December 2, 2016, Health Canada released its updated guidelines for biosimilar biologic drug submissions. The document will provide guidance to sponsors to enable them to satisfy the information and regulatory requirements for the authorization of biosimilars in Canada.
The following criteria determine the scope if products that are eligible to ... Read More
02
Dec2016
As a first step to framework modernization, the Patented Medicines Prices Review Board (PMPRB) is undertaking major consultations regarding possible reform of its Compendium of Policies, Guidelines and Procedures, commonly referred to as “the Guidelines.”
During Phase 1 of this consultation initiative, the PMPRB asked for input on how to rethink ... Read More